Overview

Treatment of Egyptian Hepatitis C Genotype 4 Infected Children and Adolescents With Combined Ledipasvir/Sofosbuvir

Status:
Unknown status

Trial end date:
2019-06-30

Target enrollment:

Participant gender:

Summary

This is an open, uncontrolled study of twenty-five chronic HCV infected patients carried out at Yassin Abdel Ghaffar Charity Center for Liver Disease and Research. The aim of this study is to investigate the safety & efficacy of combined therapy ledipasvir (LDV) and sofosbuvir (SOF) for treating HCV Genotype 4 in children aged 8 to 18. Due to previous positive results in other clinical studies of this drug it is expected that the drug will have high safety and high efficacy. Safety will be measured by checking for adverse effects, while efficacy will be measured by Real-Time Quantitative Polymerase Chain Reaction (qPCR) detecting viral nucleic acids in blood samples.

Phase:

Phase 4

Details

Lead Sponsor:

Yassin Abdelghaffar Charity Center for Liver Disease and Research

Treatments:

Ledipasvir
Ledipasvir, sofosbuvir drug combination
Sofosbuvir